NCT03605277View on ClinicalTrials.gov

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 16, 2018

Primary Completion Date

March 18, 2019

Study Completion Date

April 14, 2019

Conditions
Renal Impairment
Interventions
DRUG

Asciminib

40 mg single dose

Trial Locations (2)

1612

Novartis Investigative Site, Sofia

14050

Novartis Investigative Site, Berlin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY